Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in New Jersey
27 February 2012 | By Merck
Merck, will vigorously defend itself in a jury trial set to begin on the 27th February...
List view / Grid view
News
Samsung Biologics and Biogen Idec announce formation of biosimilars joint venture Samsung Bioepis
27 February 2012 | By Biogen Idec
Samsung Biologics & Biogen Idec have established their joint venture...
Abbott collaborates with leading U.S. forensics center on human identification testing
23 February 2012 | By Abbott
UNT Health Science Center Evaluating Abbott’s PLEX-ID System & Mitochondrial DNA Assay...
Tecan Award 2011 winner announced
23 February 2012 | By kdm communications limited
Tecan is pleased to announce the results of the Tecan Award 2011. Established in 2010 to celebrate the innovation and ingenuity of Tecan’s loyal customers...
Shareholders approve all proposed resolutions of Novartis Board of Directors
23 February 2012 | By Novartis
Dr. Dimitri Azar elected as new member of the Novartis Board of Directors for a 3yr term...
Pfizer statement regarding CDC’s ACIP discussion of Prevnar 13®
22 February 2012 | By Pfizer
Pfizer believes Prevnar 13 should be recommended for all adults 50 years of age and older...
Boehringer Ingelheim and Xencor enter a collaboration agreement
21 February 2012 | By Boehringer Ingelheim
Antibodies engineered with Xencor’s proprietary Xtend™ technology for increasing antibody half-life...
European Commission approves CAPRELSA® (vandetanib) for patients with advanced medullary thyroid cancer
21 February 2012 | By AstraZeneca
Marketing authorisation for CAPRELSA® (vandetanib) granted...
Roche’s Zelboraf receives EU approval
20 February 2012 | By Roche
First and only personalized skin cancer medicine allows people with BRAF V600 mutation-positive metastatic melanoma to live significantly longer...
Plexxikon announces European approval of Zelboraf®
20 February 2012 | By Daiichi Sankyo
The European Commission has approved Zelboraf® (vemurafenib)...
Bristol-Myers Squibb Foundation announces grants focused on prevention, diagnosis & care of Hepatitis B and Hepatitis C in Asia
18 February 2012 | By Bristol-Myers Squibb
Three new grants awarded...
Gilead announces data for genotype 1 null responder hepatitis C patients enrolled in ELECTRON study
17 February 2012 | By Gilead Sciences
Viral relapse seen post treatment with GS-7977 plus ribavirin...
Novartis to revise product information in the European Union for high blood pressure drug Rasilez®
17 February 2012 | By Novartis
CHMP concluded the risk-benefit review of Rasilez* (aliskiren)...
GSK receives positive opinion in Europe from the CHMP for Nimenrix®
17 February 2012 | By GlaxoSmithKline
The EMA's CHMP has issued a positive opinion recommending marketing authorisation for Nimenrix® (MenACWY-TT)...
CHMP recommends approval of BYETTA® for use with basal insulin
17 February 2012 | By Eli Lilly and Company
Patients in pivotal study achieved better glycemic control without weight gain...
